Radionetics Oncology

Radionetics Oncology is a private, San Diego-based biotech founded in 2021, focused on expanding the application of radiopharmaceuticals in solid tumors through its innovative GPCR-targeting platform. The company has secured a significant strategic agreement with Eli Lilly, including a $140 million upfront payment and a potential $1 billion acquisition option, validating its technology and providing substantial non-dilutive capital. With a deep leadership team experienced in GPCR biology and drug development, Radionetics is advancing a preclinical pipeline targeting cancers with high unmet need, such as breast and lung cancer, positioning itself at the forefront of the next wave in precision oncology therapeutics.

Proprietary platform for the discovery and development of novel small molecule radiopharmaceuticals targeting G protein-coupled receptors (GPCRs) overexpressed on cancer cells. Utilizes a theranostic, fit-for-purpose approach pairing optimized ligands with optimal diagnostic or therapeutic radioisotopes.

The radiopharmaceutical competitive landscape is intensifying, with major players like Novartis (Pluvicto, Lutathera), Bayer, and now Eli Lilly (via this deal and others) establishing strong positions. Radionetics competes with other GPCR-focused radiopharma companies (e.g., RayzeBio, acquired by Bristol Myers Squibb) and numerous biotechs. Its differentiation lies in its specialized small molecule GPCR platform and theranostic approach.